BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29198449)

  • 1. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
    Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
    Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE; Mesure R
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
    Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
    Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
    Young A; Anzures-Cabrera J; Derks M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
    Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
    Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
    J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of multiple oral doses of linagliptin on the steady-state pharmacokinetics of a combination oral contraceptive in healthy female adults: an open-label, two-period, fixed-sequence, multiple-dose study.
    Friedrich C; Port A; Ring A; Graefe-Mody U; Giessmann T; Iovino M; Woerle HJ
    Clin Drug Investig; 2011; 31(9):643-53. PubMed ID: 21714581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers.
    Dienel A; Klement S; Müller F
    Arzneimittelforschung; 2004; 54(3):152-9. PubMed ID: 15112861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
    Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial.
    Kothare PA; Seger ME; Northrup J; Mace K; Mitchell MI; Linnebjerg H
    BMC Clin Pharmacol; 2012 Mar; 12():8. PubMed ID: 22429273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel.
    Kapitza C; Nosek L; Jensen L; Hartvig H; Jensen CB; Flint A
    J Clin Pharmacol; 2015 May; 55(5):497-504. PubMed ID: 25475122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women.
    Falcão A; Vaz-da-Silva M; Gama H; Nunes T; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Aug; 105(3):368-76. PubMed ID: 23570863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women.
    Elgart A; Zur AA; Mimrod D; Dror V; Bar-Ilan O; Korver T; Spiegelstein O
    Eur J Clin Pharmacol; 2019 Jan; 75(1):41-49. PubMed ID: 30191262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
    Sabo JP; Lang B; Elgadi M; Huang F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.
    Katz M; DeRogatis LR; Ackerman R; Hedges P; Lesko L; Garcia M; Sand M;
    J Sex Med; 2013 Jul; 10(7):1807-15. PubMed ID: 23672269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.